|
|
 |
|
Viewing report
|
|
|
|
Psychopharmacotherapy Market Insights: Obstacles and Opportunities in Mood Disorders and Cognitive Impairment, 2005-2012
Spectra Intelligence , Nov 2005, Pages: 91
Examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012. Key factors discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified to buffer the decline include the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance. The report also evaluates the emerging market sector of cognitive and memory impairment and shows the extent of R&D activities within the field. Analysis of both sectors reveals candidates that have top-line earning prospects and also provides an insight into potential licensing or acquisition opportunities in promising psychopharmacotherapy market subsectors.
Objectives of the Report
The objectives of this report are to provide a detailed analysis of the global psychopharmacotherapeutic market related to mood disorders and cognitive impairment. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.
Research Methodology
The contents of this report are derived from in-depth research-based surveys of the industry and proprietary analytical assessment tools. Source material also comprises the following:
- Company information
- Personal communication
- Trade press articles
- News releases
- Internet-based research
- Library research
- Scientific periodicals
- Product information
- Market analyst data
- Public information datasets
- Conference proceedings
- Medical/pharma associations
REPORT HIGHLIGHTS AND KEY FINDINGS
- Pharmacotherapies indicated for mood disorders account for a market valued at US$17.4 billion, which is forecast to decrease 13.6% CAGR to US$15 billion by 2012
- Critical analysis of depression, anxiety disorders, and cognitive and memory impairment
- Review of epidemiological, aetiological, and therapeutic data for key therapy areas
- Analysis of 10 marketed products and inclusion of 88 R&D candidates identified in preclinical to clinical stages of development for depressive illnesses and cognitive impairment
- Sales estimates (US$) to 2012 for major therapy areas
- Strategic insights for life-cycle optimization and product development
- Critical evaluation of leading antidepressants
- Emerging markets identified and sector analysis
- Trend analysis of industry events and activities over past 2 years
- Detailed R&D themes and clusters by therapy area
- Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
- High revenue-yielding prospects identified with projected sales estimations
- R&D pipeline positioning for key therapy areas
- Market insights for product development and drug promotion
WHAT CAN I LEARN FROM THIS REPORT?
- Which antidepressants are the current and potential future market leaders
- Insight into the main psychopharmacotherapies for depression and anxiety disorders
- How companies optimize product life cycle through supplementary indications and
reformulation
- Which premarket antidepressants are identified as potential blockbusters
- Which companies are developing drugs for cognitive impairment and memory deficits
- Sales predictions to 2012 for leading antidepressants/anxiolytics
- What the likely impact of pipeline products will be on value growth over the next decade
- Which generic defence strategies are being employed by research-based companies
- How generic companies are becoming increasingly litigious in advance of patent expiry
- Which therapy subsectors could be niche market opportunities for depressive illnesses
- What the future outlook could be for marketed antidepressants and anxiolytics
- Insight into R&D trends for antidepressants, and drugs for cognitive impairment
- Which molecules and compounds are main R&D clusters
- What are the top prospects for mood disorders, cognitive impairment, and memory deficits over the next decade and to 2020?
Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered…
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Mild Cognitive Impairment - Unlocking the Potential of Prodromal Alzheimer's Disease and Beyond
Cognitive Impairment In Schizoaffective Disorder - Inevitable Or Treatable?
Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application - 2 Volume Set
Mild Cognitive Impairment and Early Alzheimer's Disease: Detection and Diagnosis
Anxiety Disorders - Viable Indication for Antipsychotics Companies
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
Commercial Insight: Antidepressants - Novel Mechanism Offers Hope in Depressed Market
Pipeline Insight: Depression - Novel Drugs to Grow Third-line Market
Commercial Insight: Depression - Atypical lifecycle management strategy rejuvenates depression market
Cognitive Hypnotherapy: An Integrated Approach to the Treatment of Emotional Disorders
Memory Impairment Therapy Area Pipeline Report
Stakeholder Perspectives: Mild Cognitive Impairment and Dementia - Aricept in race to pioneer unexplored markets
|
|
|
|
